The launch plan exists across the organisation. The launch truth often does not. Siloed data, fragmented ownership, and delayed visibility turn manageable risks into launch delays. Drug Launch Accelerator creates a single source of truth for readiness, governance, and execution across every market.
Readiness is scattered across spreadsheets, decks, emails, local trackers and meeting updates, making it difficult to see the real state of launch execution.
Regulatory, access, MLR, supply, medical and commercial dependencies often surface only after they have already shifted the launch path.
Gate packs and readiness reviews consume leadership time because teams rebuild status instead of governing from live evidence.
Global strategy and local execution can drift when countries report readiness through inconsistent formats, timelines and assumptions.
Completed launches often leave behind lessons in decks and memories, not reusable launch intelligence for the next brand, indication or market wave.
A governed loop from launch setup to market execution. Drug Launch Accelerator provides a structured framework to onboard products, markets, and launch strategies, orchestrate cross-functional activities, monitor readiness, govern critical decisions, and maintain complete traceability. By unifying planning, execution, compliance, and governance, it helps pharmaceutical teams deliver compliant, coordinated, and successful product launches across global markets.
Capture launch context, countries, product modality, playbooks and source material in a structured launch setup flow.
Instantiate launch clocks, workstreams, activities, dependencies, market waves and governance gates from a governed launch model.
Track readiness, blockers, risks and downstream dependency movement from live activity updates.
Run gate decisions with owners, rationale, evidence, conditions and audit trail.
Show who changed what, when, why and from which source, so launch decisions are traceable.
Convert launch execution history into reusable lessons, playbooks and institutional knowledge.
Everything launch leaders need to see, decide and prove. Drug Launch Accelerator provides a unified view of launch readiness, cross-functional execution, governance, risks, and dependencies across products and markets. By combining operational visibility with decision traceability, it enables pharmaceutical teams to accelerate launches, mitigate delays, and demonstrate compliance and accountability at every stage of the launch lifecycle.
Portfolio, market and wave visibility across readiness, launch health, risks, blockers, gates and leadership attention areas.
Country and workstream readiness across regulatory, market access, medical, commercial, supply, quality and local execution.
Go/no-go decisions, RACI, escalations, assumptions, dependency management, conditions, rationale and audit history.
Critical-path visibility that shows what is slipping, what it affects and who needs to act before the impact escalates.
Source-linked recommendations, summaries and setup support that assist teams while accountable people remain in control.
A structured learning layer that turns launch experience into reusable benchmarks, playbooks and future launch readiness intelligence.
Move from reactive reporting to launch confidence. Drug Launch Accelerator equips pharmaceutical launch teams with the visibility, governance, and intelligence needed to proactively manage risks, accelerate decision-making, and improve launch readiness. By turning fragmented launch activities into a coordinated operating model, it helps organizations achieve more predictable, compliant, and successful product launches across global markets.
Earlier risk visibility
Give launch teams time to intervene before critical dependencies become launch delays.
Faster governance readiness
Reduce manual gate-pack preparation by running reviews from live launch data and traceable evidence.
Stronger cross-functional alignment
Bring global, regional, country and workstream teams into one shared launch operating model.
Clearer executive decisions
Surface the markets, gates, risks and blockers that require leadership attention.
Higher launch discipline
Make readiness measurable, ownership visible and decisions auditable.
Reusable launch intelligence
Carry lessons, patterns and playbook improvements into the next launch.
Launch readiness, gate status, critical-path dependencies, blockers, mitigations and decision history.
Local readiness, market-specific activities, country blockers, launch wave status and go/no-go inputs.
Submission, label, packaging, health authority milestones and country-level dependency context.
HTA, pricing, reimbursement, payer milestones and access-driven launch sequencing risks.
Field readiness, campaign readiness, content approval status, medical engagement and evidence-readiness visibility.
Release readiness, safety obligations, distribution readiness, supply checkpoints and market availability constraints.
Integration-ready by design: Designed to sit above systems such as regulatory, MLR, ERP, CRM, finance, data platforms and document repositories, while preserving their role as systems of record.
Configurable launch model: Launch clocks, countries, market waves, modalities, readiness weights, gates and governance logic can be adapted to different organisations and launch archetypes.
Role-scoped access: Users see the information relevant to their role, market, workstream and governance responsibility.
Audit-ready traceability: Critical changes, gate decisions, recommendations and approvals are recorded with ownership and context.
Human-governed intelligence: AI can recommend, summarise and support launch setup, but accountable people decide.
Drug Launch Accelerator connects with a trusted ecosystem of pharmaceutical, regulatory, commercial, and technology partners to streamline launch operations and improve market readiness. By integrating data, workflows, and governance across the launch landscape, these partnerships help organizations accelerate execution, reduce risk, and deliver successful product launches with greater confidence and control.
Explore insights, case studies, and expert perspectives on pharmaceutical launch readiness, governance, and market execution. These resources highlight how launch teams are reducing risk, accelerating governance, and driving measurable launch confidence.
Blog
Blog
Blog
Case Study
Blog
Guide
Guide
Guide
Case Study
Case Study
Case Study
Case Study
Case Study
Case Study
Drug Launch Accelerator is used to orchestrate global pharmaceutical launch planning, readiness, risk, governance and market execution across functions, regions and countries.
The platform is designed for executive leadership, global launch leaders, regional and country teams, regulatory, market access, commercial, medical, quality, PV, supply and launch excellence teams.
No. It is intended to orchestrate launch execution across existing systems, not replace regulatory, CRM, ERP, MLR, finance or document systems of record.
It gives teams a live view of readiness, dependencies, risks, gates, owners and decisions, reducing reliance on manually rebuilt governance packs.
Intelligence is designed to support recommendations and summaries while accountable users review, confirm and own decisions.
